期刊文献+

伊曲康唑注射液治疗恶性血液病侵袭性真菌感染的临床研究 被引量:2

Efficacy of intravenous itraconazole on invasive fungal infections in patients with hematological malignancies
下载PDF
导出
摘要 目的:研究伊曲康唑注射液治疗血液恶性病患者合并侵润性真菌感染的疗效。方法:对30例按标准诊断患者应用伊曲康唑注射液,剂量200~400mg/d第1天,以后200mg/d用药14天。结果:临床总有效率为66.7%,确诊病例、临床诊断病例与拟诊病例有效率分别为71.3%、86.3%、25.0%。确诊病例、临床诊断病例与拟诊病例有效率之间相比,有统计学差异(P〈0.05);粒细胞减少,应用广谱抗生素及糖皮质激素是发病的主要危险因素;伊曲康唑注射液起效时间3天-7天,中位时间4天。结论:伊曲康唑注射液对恶性血液病合并侵袭性真菌感染疗效显著,对存在危险因素的患者早期诊断,积极治疗,可取得良好效果。 Objective: To investigate the efficacy of intravenous administration of itraconazole on invasive fungal infections(IFI) in patients with hematological malignancies, nethods: Thirty patients with hematological malignancies who were diagnozed according to the criteria of invasive fungal infections underwent intravenous injection of itraconazole 200mg bid for first day and then qd for at least 2 weeks. Results: The total effective rate was 66.7%. The effective rates of the patients with confirmed diagnosis, clinical diagnosis, and with recommended diagnosis respectively were 71.3%, 86.3% and 25.0% ,there was a significant difference between the patients with confirmed diagnosis, clinical diagnosis and patients with recommended diagnosis( P 〈0. 01 ). The main danger factors of IFI were neutrocytopenia, administration of broad - spectrum antibiotic and glucocorticoid for a long - time. Conclusion: Itraconazole injection is effective and safe in treatment of invasive fungal infections in patients with hematological malignancy .
出处 《现代肿瘤医学》 CAS 2007年第2期242-243,共2页 Journal of Modern Oncology
关键词 侵袭性真菌感染 伊曲康唑 恶性血液病 itraconazole invasive fungal infections hematological malignancy
  • 相关文献

参考文献8

二级参考文献33

  • 1郝飞.伊曲康唑在系统性真菌感染防治中的价值[J].中华内科杂志,2003,42(11):814-816. 被引量:2
  • 2Sigler L,Kennedy MJ.Aspergillus,fusarium,and other opportunistic Moniliaceous fungi[A].Murray PR,Baron EJ,Pfaller MA,et al.Manual of cinical microbiology[M].7th Ed.Washington DC:ASM Press,1999.1213-1241.
  • 3Pfaller MA,Messer SA,Mills K,et al.In vitro susceptibility testing of Filamentous fungi:comparison of Etest and reference microdilution methods for determining itroconazole MICs[J].J Clin Micro,2000,38(9)∶3359-3361.
  • 4National Committee for Clinical Laboratory Standards.Reference method for broth dilution antifungal susceptibility testing of condidiumforming filamentous fungi.Proposed standard M38-P.National Committee for Clinical Laboratory Standard[S].Wayne.Pa.1998.
  • 5Espinel-Ingroff A,White T,Pfaller MA.Antifungal agents and susceptibility tests[A].Murray PR,Baron EJ,Pfaller MA,et al.Manual of cinical microbiology[M].7th Ed.Washington DC:ASM Press,1999.1640-1652.
  • 6Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patientsat a university hospital. Bone Marrow Transplant, 2002 ,29:15-19.
  • 7Ninin E, Milpied N, Moreau P, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis, 2001, 33:41-47.
  • 8Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infection in allogeneic bone marrow transplant recipients. Clin Infect Dis,2001,32:1319-1324.
  • 9Wakayama M, Shibuya K, Ando T, et al. Deep-seated mycosis as a complication in bone marrow transplantation patients. Mycoses, 2002,45:146-151.
  • 10Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus. Clin Infect Dis, 2002,34:7-14.

共引文献486

同被引文献23

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部